PHARMING

PHARMING RECIEVES ORPHAN DRUG DESIGNATIONS FOR RHC1INH FROM US FDA

Leiden, The Netherlands, June 14, 2006. Biotech company Pharming Group NV ("Pharming" or "the Company") (Euronext: PHARM) announced today it has received orphan drug designations for recombinant human C1 inhibitor (rhC1INH) from the Food and Drug Administration (FDA). The Company has obtained designations on rhC1INH for two separate disease indications - the prevention and/or the treatment of Delayed Graft Function (DGF) after solid organ transplantation and the treatment of Capillary Leakage Syndrome (CLS).

Over 25,000 solid organs were transplanted in the US in 2005, including kidney, liver, lung and heart transplants. Delayed Graft Function is a common complication affecting all solid organs in the post-transplant period. DGF results in significant morbidity and mortality from early graft dysfunction and from decreased long-term graft survival. The condition also prolongs hospitalization and requires substitute therapies for these patients, such as dialysis or ventilatory support. DGF remains a critical unmet medical need despite improvements in immunosuppression, organ preservation, and surgical technique. C1 inhibitor has been shown in numerous models of organ transplantation to improve early graft function.

Over 100,000 patients in the US develop Capillary Leakage Syndrome annually as a complication of various disease states, including bone marrow/stem cell transplantation, IL-2 therapy, sepsis, and neonatal cardiac surgery. CLS is a severe life-threatening condition characterized by excessive fluid loss into the tissue space, which can result in hemodynamic instability, pulmonary edema, ascites, and death. Current therapies for patients with CLS are limited to supportive care and treatment of the underlying condition. Previous clinical work has demonstrated that C1 inhibitor may be an effective anti-inflammatory that can control the mechanisms contributing to CLS.

"Pharming's rhC1INH product could provide new treatments for immune mediated diseases such as Delayed Graft Function in organ transplantation and Capillary Leakage Syndrome, conditions with a high burden and limited treatment options for patients," said Dr. Francis Pinto, CEO of Pharming. "The Orphan Drug designations from the FDA further validate the potential of rhC1INH as an innovative therapy and are a significant achievement as we advance development of rhC1INH for these indications."

The FDA Orphan Drug designation is reserved for promising new therapies being developed to treat diseases that affect fewer than 200,000 people in the United States. This designation provides an accelerated review process, tax advantages and a seven-year period of market exclusivity in the US upon product approval. Pharming also has an Orphan Drug designation on rhC1INH for the treatment of Hereditary Angioedema.

Background on Pharming Group NV

Pharming Group NV is developing innovative protein products for unmet needs. The Company's products include potential treatments for genetic disorders, specialty products for surgical indications, intermediates for various applications and food products. Pharming has two products in late stage development - recombinant human C1 inhibitor for Hereditary Angioedema (Phase III) and recombinant human lactoferrin for use in functional foods. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website: http://www.pharming.com.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.

Contact:

Carina Hamaker
Investor Voice
T: +31 (0)6 537 49959

Sarah MacLeod
Financial Dynamics
T: +44 (0)20 7269 7148

Samir Singh
Pharming Group NV
T: +31 (0)71 524 7429